Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.63 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.63 |
| ▸ | CDK2 | P24941 | 2/20 | 0.63 |
| ▸ | CDK9 | P50750 | 2/20 | 0.63 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.58 |
| ▸ | AURKA | O14965 | 3/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.51 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036236 | 0.86 | GLO1 (0.66) | CCNT1CCNE1CDK2CDK9GLO1 | |
| SCHEMBL1037328 | 0.85 | GLO1 (0.63) | CCNT1CCNE1CDK2CDK9GLO1 | |
| SCHEMBL1036297 | 0.84 | GLO1 (0.62) | CCNT1CCNE1CDK2CDK9GLO1 | |
| SCHEMBL1037308 | 0.84 | GLO1 (0.62) | CCNT1CCNE1CDK2CDK9GLO1 | |
| SCHEMBL1038420 | 0.83 | GLO1 (0.59) | CCNT1CCNE1CDK2CDK9GLO1 | |
| SCHEMBL1038762 | 0.82 | GLO1 (0.59) | CCNT1CCNE1CDK2CDK9GLO1 | |
| SCHEMBL1040138 | 0.81 | GLO1 (0.69) | GLO1AURKAALKMETMAPK8 | |
| SCHEMBL1038297 | 0.81 | GLO1 (0.72) | CDK2GLO1AURKANTRK1ALK | |
| SCHEMBL600716 | 0.81 | ALK (0.54) | GLO1ALKMETLRRK2 | |
| SCHEMBL1039144 | 0.80 | GLO1 (0.83) | CDK2GLO1AURKANTRK1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | claimed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | claimed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | CCNT1 2367/4885CCNE1 2871/4885CDK2 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.